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Abstract 
Background: The screening for intestinal carriage of vancomycin-resistant Enterococcus spp. (VRE) among high risk 
patients in the Balkan region and molecular epidemiology of VRE is insufficiently investigated, yet it could be of key 
importance in infection control. The aim of this study was to provide baseline data on VRE intestinal carriage among 
high-risk patients in Serbian university hospitals, to determine the phenotypic/genotypic profiles of the isolated VRE, 
to obtain knowledge of local resistance patterns and bridge the gaps in current VRE surveillance.
Methods: The VRE reservoir was investigated using stool samples from 268 inpatients. Characterization of isolated 
VRE stains consisted of BD Phoenix system, genotypic identification, glycopeptide and quinupristin–dalfopristin (Q–D) 
resistance probing, virulence gene (esp, hyl, efaA, asa1, gelE, cpd) detection and MLVA. Biofilm formation was evaluated 
by the microtiter plate method.
Results: VRE carriage prevalence among at-risk patients was 28.7%. All VRE strains were vanA positive multidrug-
resistant Enterococcus faecium (VRfm), harboring ermB-1 (38.9%), esp (84%), efaA (71.2%), hyl (54.5%), asa1 (23.4%), gelE 
and cpd (11.6%) each. Ability of biofilm production was detected in 20.8%. Genetic relatedness of the isolates revealed 
13 clusters, heterogeneous picture and 25 unique MTs profiles.
Conclusion: The obtained prevalence of VRE intestinal carriage among high-risk inpatients in Serbia is higher than 
the European average, with high percentage of multidrug resistance. The emergence of resistance to Q–D is of 
particular concern. Close monitoring of pattern of resistance and strict adherence to specific guidelines are urgently 
needed in Serbia.
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Introduction
Vancomycin resistant enterococci (VRE) have emerged 
as one of the most important health-care associated 
(HA) multidrug-resistant (MDR) pathogens, caus-
ing invasive infections, especially in severely ill and 
immunocompromised patients [1–3]. Limited thera-
peutic options for the treatment of VRE infections, the 
ability of VRE to survive in hospital environment, the 
capability to colonize the digestive tract of patients and 
the capacity for acquiring and transferring resistance 
genes along with the danger of vancomycin-resistant 
Staphylococcus aureus occurrence are the reasons that 
VRE was identified as an ESKAPE pathogen (Ente-
rococcus faecium, Staphylococcus aureus, Klebsiella 
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pneumoniae, Acinetobacter baumanni, Pseudomonas 
aeruginosa i Enterobacter species) [4] and recently 
selected as a high priority pathogen in the global prior-
ity pathogens list of the The World Health Organiza-
tion for the development of new antibiotics [1–3, 5–7].
VRE colonization often precedes infection [8, 9] 
and numerous studies have identified hospital wards 
as places where VRE colonization poses the greatest 
risk to human health, in particular hematology, oncol-
ogy, dialysis, intensive care units (ICUs), geriatrics and 
acute infectious diseasese wards [2, 3, 10–13]. Previ-
ous studies have shown that the prevalence of VRE 
colonization among hospital patients in Europe varies 
from 2 to 37% [3, 14].
Strategies to control the transmission of VRE in hos-
pital settings include screening, early identification 
of colonization and the isolation of high risk patients 
[1, 2, 5, 9, 15]. The information about intestinal car-
riage and molecular epidemiology of VRE among at-
risk patients in the Balkan region is scarce. Therefore, 
case-based surveillance [16] through which the base-
line data can be obtained on the prevalence of VRE 
intestinal carriage as well as molecular epidemiology 
studies of circulating VRE stains in high-risk units are 
needed.
The first case of VRE in Serbia was reported in 2002 
in the Clinical Center of Serbia (CCS), the largest ter-
tiary-care teaching hospital in Serbia, which is also a 
major referal center for neighboring countries of ex-
Yugoslavia (Montenegro, Bosna and Herzegovina) [17]. 
Sixteen years later, according to the data of the Cen-
tral Asian and European Surveillance of Antimicrobial 
Resistance network [18], among invasive enterococci 
in Serbia vancomycin resistance was found in 54% of 
Enterococcus faecium and in 5% of Enterococcus faeca-
lis isolates. These results were suggested to reflect hos-
pital acquired infections and clone dissemination [18].
As hospital acquired VRE infections could be the 
tip of the iceberg [9] the aim of this study was to pro-
vide baseline data on VRE intestinal carriage among 
patients at high risk departments for VRE colonization 
in major Serbian university hospitals and to determine 
the full antibiotic susceptibility profiles along with fre-
quency of resistance to individual drugs, biofilm pro-
duction capacity and genetic relatedness of the isolated 
VRE. We also sought to bridge the gaps in current VRE 
surveillance in the Balkan region regarding screen-
ing data for pateints in high risk areas as part of a new 
concept of case-based surveillance [16] and to enhance 
the role of microbiology laboratory as a key partner in 
survaillance of antimicrobial resistance (AMR).
Materials and method
Study design and setting
The intestinal VRE reservoir was investigated by mul-
ticenter cross-sectional study in six hospital depart-
ments of university hospitals in Serbia over the period 
of 1.5 years (from June 2015 to January 2017): geriatrics, 
29 beds; ICUs, 22 beds; hemato-oncology, 25 beds; acute 
infective disease, 21 beds; hemodialysis, 31 beds.
The sample size was calculated using Epi info™ 7 (CDC, 
USA) statistical software. Parameters used to calculate 
the sample size were: expected frequency of colonized 
patients with VRE strains in the hospital population of 
18% [14], with a 95% confidence interval and acceptable 
margin of error of 5%. Accordingly, the sample size was 
calculated to be 227.
Participation was voluntary and comprised inpa-
tients aged 18 years and older, of both sexes, who signed 
informed consent form prior to their inclusion in the 
study. The study was approved by The Ethical Boards of 
the included University hospitals: CCS, Zvezdara Univer-
sity Medical Centre (ZvUMC), Zemun University Medi-
cal Centre (ZmUMC). Important to note is that Serbia is 
a middle income Southeastern European country, with 
about seven million inhabitants, of which roughly 1/4 
lives in Belgrade.
Isolation
Stool samples for VRE testing were collected from 268 
inpatients in sterile containers and were processed 
within 2  h after collection. Chromogenic agar medium 
(CHROMID®VRE, bioMerieux, France) was used for 
VRE screening. Stool samples were directly plated. 
In accordance with the manufacturers’ recommenda-
tions, plates were incubated at 36 ± 1  °C in ambient air, 
examined for growth after 24 h and 48 h and violet and 
blue-green colonies were presumptively identified as 
vancomycin resistant Enterococcus faecium (VREfm) 
or vancomycin resistant Enterococcus faecalis (VREfs), 
respectively. Three to four VRE colonies were inoculated 
into 1 mL of sterile Tryptic soy broth (TSB, Torlak, Ser-
bia) and overnight cultures were microscopically exam-
ined for purity. Overnight cultures were placed in 10% 
glycerol and stored at − 72 ± 1 °C until future processing. 
Prior to testing, isolates were subcultured onto Columbia 
agar with 5% sheep blood (Torlak, Serbia).
Identification to the species level and antimicrobial 
susceptibility testing
Identification and antimicrobial susceptibility test-
ing were performed using the BD Phoenix™ automated 
microbiology system (BD, USA) with Gram Positive 
Combo Panels (PMIC/ID-94, BD, USA). Interpretation of 
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results and quality control were performed in accordance 
with the latest version of the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) recom-
mendations (v 10.0) [19].
Molecular identification and detection of resistance 
and virulence genes
DNA isolation was performed from the pellet of 5  mL 
overnight cultures. The pellet was resuspended in 200 µL 
of TE buffer with 0.1 mm glass beads. After vortexing egg 
white lysozyme and achromopeptidase were added and 
incubated for 2  h at 36 ± 1  °C. Two freeze–thaw cycles 
were performed. Subsequently, 30  μl lysis buffer was 
added and diluted with 180 μl buffer (10 mM Tris–HCl, 
pH 8.5). Cell lysates were centrifuged at 16,000×g for 
5 min. DNA from the supernatant was precipitated using 
ethanol and dissolved in water.
Multiplex polymerase chain reaction (PCR) was per-
formed to detect genes for species identification (ddlE. 
faecium, ddlE. faecalis) and for detection of resistance to 
vancomycin (vanA, vanB, vanC1, van C2/C3) [20–22]. 
Another multiplex PCR was performend to detect Quin-
upristin–dalfopristin (Q–D) resistance genes (vatD, vatE, 
vgbA, ermB-1) [23].
The presence of six virulence genes was tested in this 
study: esp, hyl, efaA, asa1, gelE, and cpd [24, 25]. In this 
analysis two multiplex PCRs were performed.
For PCR reactions Fast Gene Taq Ready Mix with dye 
(NIPPON Genetics, EUROPE GmbH) or Fusion Hot 
Start II High Fidelity Master Mix (Thermo Scientific, 
USA) were used as apropriate. Amplified products were 
analyzed with 1.5% w/v agarose gel. As molecular weight 
size marker 100  bp DNA Ladder (H3 RTU, NIPPON 
Genetics, EUROPE GmbH) was used.
MLVA typing
VREfm isolates were genotyped using Multiple-locus var-
iable-number tandem-repeat (VNTR) analysis (MLVA) 
which was performed using a previously described 
method [26] with minor modification. An initial denatur-
ation at 95 °C for 5 min was used for all cycles. VNTR-2 
Touch Down (TD) PCR was done with decreasing 
annealing temperature for 0.7 °C at each cycle during the 
next 9 cycles and during the next 35 cycles, an anneal-
ing temperature of 63 °C was used. VNTR-9 TD PCR was 
done as follows: 10 cycles of 30 s at 94 °C, 30 s at 70 °C 
and 1 min at 72 °C with annealing temperature decreas-
ing for 0.6 °C at each cycle during the next 9 cycles and 
during the next 35 cycles an annealing temperature of 
64  °C was used. For VNTR-7, VNTR-8 and VNTR-10 
PCR involving 35 cycles and an annealing temperature of 
55 °C was used.
Cluster analysis of MLVA data was performed by Bio-
Numerics software (version 7; Applied Maths) using 
UPGMA (Unweighted-pair group) clustering method 
with categorical coefficient of similarity. Cut-off value for 
clustering was set on 85% of similarity with a minimum 
of 2 members in a cluster and Simpson’s index of diver-
sity was calculated. MLVA types (MTs) were assigned by 
comparison with the existing MLVA base [26]. For new 
combinations of MLVA profiles, new MTs were assigned. 
They were named according to the country of isolation 
(SRB) followed by incrising number obtained from phy-
logenetic analyses.
Biofilm formation assay
The ability of isolated VRE to form biofilm was tested by 
microtiter plate method [27] in 96-well flat-bottomed 
polystyrene plates using TSB supplemented with 1% 
glucose and crystal violet staining. The absorbance of 
each plate was measured at 580  nm using a microtiter 
plate reader and the results were calculated according to 
Stepanović et al. [27].
Results
A total of 268 inpatients were tested, of which 77 (28.7%) 
were intestinal carriers of VREfm strains, with vanA gen-
otypic profile and VanA phenotypic profile. The frequen-
cies of VREfm carriage among patients hospitalized in 
the aforementioned departments are shown in Table 1.
The analysis of antibiotic susceptibility, shown in 
Table  2, exposed high prevalence of multidrug-resistant 
VRE strains. In addition to vancomycin and teicoplanin 
resistance, 23.4% (18/77) VREfm isolates were resistant 
to all remaining antimicrobial drugs, except linezolid and 
tigecyclin to which all the isolates were susceptible. Addi-
tionaly, 38.9% of VREfm strains were resistant to Q–D.
Phenotypic resistance profiles of the isolated VREfm 
strains are shown in Table 3.
Table 1 Distribution of isolated Vancomycin-resistant 
Enterococcus faecium (VREfm) stratified by investigated hospital 
departments







Acute infectious diseases 10/44 22.7
Hemodialysis 6/51 11.7
Total 77/268 28.7
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Biofilm quantitative test showed that 20.7% (16/77) 
bacterial strains were biofilm producers with different 
capacity. Biofilm production capacities of given patho-
gens are shown in Table 4.
Molecular genetic analysis for molecular confirma-
tion of Q–D resistance was performed on DNA samples 
obtained from purified isolates. The analysis confirmed 
that all isolates showing phenotypic resistance carried 
the ermB-1 gene. Other genes associated with resistance 
to Q–D (vatD, vatE, vgbA) were not detected. Genetic 
analysis of the presence of virulence genes revealed that 
Table 2 Antibiotic resistant profile of Vancomycin-resistant 
Enterococcus faecium (VREfm) isolates (N = 77)
n number of VREfm isolates resistant to tested antimicrobial drug, AMP 
ampicillin, IMP imipenem, CIP ciprofloxacin, LEV levofloxacin, GEN-HLS 
gentamicin-high level aminoglycoside resistance, STR-HLS streperomicin-high 
level aminoglycoside resistance, TEI teicoplanin, Q–D quinupristin–dalfopristin, 
TIG tigecyclin, LIN linezolid













Table 3 Phenotipic profile of isolated Vancomycin-resistant 
Enterococcus faecium (VREfm)—antimicrobial susceptibility 
pattern
AMP ampicillin, IMP imipenem, CIP ciprofloxacin, LEV levofloxacin, GEN-HLS 
gentamicin-high level aminoglycoside resistance, STR-HLS streperomicin-high 
level aminoglycoside resistance, TEI teicoplanin, Q–D Quinupristin–dalfopristin
Antimicrobial susceptibility pattern Resistant
n %
AMP IMP CIP-LEVO GEN-HLS STR-HLS TEI 48 62.3
AMP IMP CIP-LEVO GEN-HLS STR-HLS TEI Q–D 18 23.4
CIP-LEVO GEN-HLS STR-HLS TEI Q–D 4 5.2
AMP IMP CIP-LEVO STR-HLS TEI Q–D 2 2.6
AMP IMP CIP-LEVO GEN-HLS TEI Q–D 2 2.6
CIP-LEVO GEN-HLS TEI 1 1.3
AMP IMP TEI Q–D 1 1.3
TEI Q–D 1 1.3
Total 77 100
Table 4 Phenotipic profile of isolated vancomycin-resistant 
Enterococcus faecium (VREfm)—biofilm production capacity
weak biofilm producer—category 1, +; moderate biofilm producer—category 2, 
++; strong biofilm producer—category 3, +++; no—no biofilm formation







Table 5 Characteristics of isolated Vancomycin-resistant 
Enterococcus faecium (VREfm) – genotypic profile
ddlE. faecium, d-alanine–d-alanine ligase gene specific for E. faecium; ddlE. faecalis, 
d-alanine–d-alanine ligase gene specific for E. faecalis; van A, type A vancomycin 
resistance; vanB, type B vancomycin resistance; vanC (C1and C2/3)—type C 
vancomycin resistance; vat(D) and vat(E) , streptogramin A resistance; vgb(A) 
and ermB-1- streptogramin B resistance; esp, Enterococcal surface protein; 
hyl, hyaluronidase; efaA, cell wall adhesine; asa1, aggregation substance; gelE, 
gelatinase; cpd, sex pheromones
Genotypic profile N %
Identification genes
 ddlE. faecium 77 100
 ddlE. faecalis 0 0
Vancomycin resistance genes
 vanA 77 100
 vanB 0 0
 vanC(C1and C2/3) 0 0
Q–D resistance genes
 vatD 0 0
 vatE 0 0
 vgbA 0 0
 ermB-1 30 38.9
Virulence genes
 esp 65 84
 efaA 55 71.2
 hyl 42 54.5
 gelE 9 11.6
 asa1 18 23.4
 cpd 9 11.6
Number of virulance genes
 0 8 10.4
 1 4 5.2
 2 20 26.0
 3 34 44.0
 4 4 5.2
 5 4 5.2
 6 3 4.0
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84% VREfm isolates harbored the esp gene, while three 
isolates harbored all tested virulence genes (Table 5).
In order to assess the genetic relatedness of the VREfm 
isolates a standard MLVA analysis was performed on 
isolated DNA samples. A total of 72/77 (93.5%) isolates 
generated a MLVA profile, while MLVA profiles could not 
be assigned for 5/77 (6.5%) isolates. MLVA revealed 29 
different MTs, of which 25 were not previously detected 
and had unique profiles. Simpson´s index of diversity was 
94%.
Genetic relatedness analysis of the isolates revealed 13 
clusters which comprised 56/72 (77.7%) of the isolated 
VREfm strains (Fig. 1). Three of 13 clusters included 12 
(SRB2), 9 (SRB16) and 7 (MT161) isolates each, while 
the 10 remaining clusters included 2 to 4 isolates. The 
remaining 16/72 (22.2%) VREfm isolates had unique gen-
otypes and were not clonally related to the other isolates. 
Next we sought to determine the association of genotype 
with the location of inpatient from which the VREfm 
was isolated. We detected that the isolates belonging to 
the larger clusters were dispersed among different hospi-
tal departments (Fig. 1). Interestingly, isolates belonging 
to the 3 minor clusters (SRB6, SRB9, SRB12) originated 
from hematology department only.
Discussion
In the last 15  years, VREs derived as a major cause of 
HA infections worldwilde due to intrinsic and acquired 
resistance to various classes of antimicrobial drugs, scar-
city in treatment options and high tendency to become 
endemic in the hospital environment [28]. European 
Centre for Disease Prevention and Control points out an 
increasing trend in the number of VREfm infections and 
VREfm associated deaths in European countries and its 
contribution to European health burden of antimicrobial 
resistance, highlighting the urgency for better under-
standing molecular epidemiology of circulating VRE [28]. 
VRE colonization often precedes infection and selective 
screening of at-risk patients for VRE colonization is one 
of the infection controling measures recommended for 
prompt identification and isolation of carriers, thus being 
the crutial step in control of patient-to-patients transmis-
sion [2, 3, 8, 9].
This study presents the first case-based surveillance 
report on the prevalence of VRE intestinal carriage 
among high-risk inpatients in Serbia and partially in the 
ex-Yugoslav region. The intention was to broaden aware-
ness and increase knowledge on VRE intestinal carriage 
in the Balkan region as well as to provide baseline data 
regarding molecular epidemiology and genetic diversity 
of circulating VRE strains in Serbia.
VRE carriage was found in 28.7% of the study popu-
lation. This frequency is high compared to low preva-
lence European countries, e.g. the Netherlands (2%) and 
Belgium (3.5%) but similar to frequencies reported in 
studies from Ireland (19.1%), United States of America 
(USA) (33%) and certain regions of France (37%) [3, 14, 
29]. However, comparison of the data form different 
countries is very difficult and should be done carefully 
as there are many variables to be taken into account. For 
example, there could be differences in the study period, 
the primary diagnosis, in the particular hospital units 
investigated, in the type of the analyzed specimens and in 
the media used for isolation. Additionally there could be 
differences in reporting of acquired and intrinsic resist-
ance profiles which may have significant impact on the 
obtained results.
In this study, we used the direct plating method of stool 
specimens onto selective chromogenic agar medium for 
the detection of the acquired VREfs and VREfm strains. 
Several studies [3, 30] evaluated usefulness of the selec-
tive chromogenic media in the detection of VRE colo-
nization, which can explain the high rate of recovery of 
VRE in our study.
All detected VRE strains were VREfm with vanA gen-
otypic profile and VanA phenotypic profile, which is 
typical for European counties [1, 2]. Similar to the study 
of Whelton et al. [29], neither VREfs nor Enterococcus 
gallinarum/casseliflavus were isolated in our research. 
Predominance of multidrug-resistant VREfm may 
indicate that the strategy of making hospital environ-
ment its novel ecological niche has been successfully 
mastered by the bacteria. This is in line with previous 
Fig. 1 Dendogram of Vancomycin-resistant Enterococcus faecium isolates using Unweighted pair group clustering method. VNTR, variable-number 
tandem-repeat; MT-MLVA type; HO, Haematology-Oncology; Ger, Geriatrics; ICU, Intensive Care Units; AID, Acute Infection Diseases; HD, 
Haemodyalisis; AMP, Ampicillin; IMP, Imipenem; CIP, Ciprofloxacin; LEV, Levofloxacin; GEN-HLS, Gentamicin-high level aminoglycoside resistance; 
STR-HLS, Streperomicin-high level aminoglycoside resistance; VAN, Vancomycin; TEI, Teicoplanin; Q–D, Quinupristin–dalfopristin; ddlE. faecium, 
d-alanine–d-alanine ligase gene specific for E. faecium; ddlE. faecalis, d-alanine–d-alanine ligase gene specific for E. faecalis; van A, type A vancomycin 
resistance; vanB, type B vancomycin resistance; vanC (C1and C2/3)—type C vancomycin resistance; vat(D) and vat(E), streptogramin A resistance; 
vgb(A) and ermB-1, streptogramin B resistance; esp, Enterococcal surface protein; hyl, hyaluronidase; efaA, cell wall adhesine; asa1, aggregation 
substance; gelE, gelatinase; cpd, sex pheromones; N, no virulence genes; +, weak biofilm producer; ++, moderate biofilm producer; +++, strong 
biofilm producer;–, no biofilm production
(See figure on next page.)
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conclusions that multidrug resistant E. faecium is a 
dominant reservoir of acquired vancomycin resistance 
in hospitals, particularly among immunocompromised 
patients, resulting in dissemination of resistance genes 
among the bacterial population upon selective antibi-
otic pressure [2, 5].
Interestingly, high rate of resistance to Q–D (38.9%) 
in VREfm isolates was found. Q–D is a streptogramin, 
antimicrobial drug licensed for treatment of infections 
caused by MDR bacteria, including VREfm. Although 
resistance to this drug among VREfm is known, it is rare 
in human isolates [31]. Moreover, Q–D is not licensed for 
clinical use is Serbia. Thus, the high frequency of resist-
ance to Q–D among VREfm strains in Serbia is of spe-
cial concern for two reasons. Firstly, the ability of VREfm 
strains resistant to Q–D to spread and cause healthcare-
associated outbreaks is potentially high. Secondly, treat-
ment options for infections caused by these strains are 
narrowed. We found that all VREfm isolates resistant to 
Q–D harbored the ermB-1 gene, that conferred resist-
ance to macrolides, lincozamine and streptogramine B, 
which is in line with previous findings [31]. Considering 
that Q–D is not licensed for clinical use in Serbia and 
that it has never been a part of therapeutic protocols in 
Serbia, possible explanation for Q–D resistance in addi-
tion to vancomycin resistance is the exchange of resist-
ance genes between E. faecium from human and animal 
sources, as resistance to Q–D is common in isolates 
retrieved from animals and is linked to the use of virgina-
mycin as growth promotion factor [23, 31].
In order to better understand VRE colonization and 
its implication in infection, we studied virulence factors. 
Obtained results showed that almost all tested virulence 
genes (esp, hyl, efaA, asa1, gelE, cpd) were present in ana-
lysed VREfm strains. Additionally, 58.4% of the isolates 
were found to carry a minimum of 3 known virulance 
genes, which is in contrast to the findings of Billström 
[32] where only 2% of isolates carried multiple virulence 
genes. Our data showed that VREfm with all the viru-
lence factors seems to be equipped to survive and spread 
in hospital environment. This ability to collect various 
virulence genes may be explained by adaptive mecha-
nisms, e.g. “genetic capitalism” due to the gene transfer 
and recombination [33–35]. Recently, Freitas et  al. [36] 
has shown that the number of virulence genes present in 
VREfm correlate well with ampicillin-resistant phenotype 
and that VREfm strains with higher ampicillin minimum 
inhibitory concentration values have higher number of 
virulence genes, which contributes to their pathogenicity. 
Almost all VREfm strains from our study were resistant 
to ampicillin and most of them contained several viru-
lence genes and therefore might pose a serious risk for 
infection in at-risk patients.
Finaly, in our study we performed MLVA typing, fast, 
cheap, easy-to-use, PCR-based method recommended 
as an initial rapid screening typing tool for the analysis 
of phylogenetic relatedness of isolated VREfm in hospi-
tal settings [26, 37]. The largest isolated clusters (SRB2, 
MT 161 and SRB16) represent single-locus variant (SLV) 
or double locus variants of MT- 340 and MT-159, known 
to cause infections in hospitalizied patients in Serbia [38, 
39]. Namely, MLVA-C1 genogroup comprises the major-
ity of epidemic and clinical VREfm isolates, with MT-1 
and its SLV MT-159, being the most common types 
associated with hospital outbreaks and invasive infec-
tions in the last decade in Europe [39]. Therefore, our 
results might indicate an evolution in hospital-adopted 
clones which might happen sporadically. Simpson’s index 
of diversity demonstrated high diversity among the iso-
lates, implying phylogenetic unrelatedness. Being that 
we found five isolates which could not be classified by 
MLVA, possibly as a result of lacking one to three VNTR 
loci, as well as 25 unique MTs, one could speculate that 
the origin of vancomycin resistance in E. faecium in our 
study is due to the horizontal gene tranfer and selective 
antibiotic pressure [33, 34, 40]. Indeed, high prevalence 
of VREfm was found in geriatrics departments where 
vancomycin is a common agent for Clostridioides dif-
ficile infection treatment. Also, broad-spectrum antimi-
crobial therapy is the most common therapeutic protocol 
in ICUs, while vancomycin is commonly used as part of 
empiric therapy of febrile neutropenia in hematological 
patients [10, 13]. Hence, unlike the rest of Europe, where 
the origin of VRE in hospitals is connected to the usage 
of avoparcin in farm animals, in Serbia we noticed a dif-
ferent scenario, likely similar to that in the USA, where 
VRE in hospitals is due to the overuse of vancomycin [2].
Although definitive proof of patient-to-patient trans-
mission requires high resolution typing techniques like 
multilocus sequence typing and whole genome sequenc-
ing [9, 41], we consider MLVA to be a reliable typing 
method in the context of infection control surveillance 
where primary focus is the exclusion of clonal relatedness 
among isolates and timely alert if an outbreak investiga-
tion is about to commence.
Conclusion
The obtained prevalence of VRE intestinal carriage 
among high-risk inpatients in Serbia is higher than the 
European average, with high percentage of multidrug-
resistance and the ability of biofilm production. Vari-
ous virulence genes might affect the pathogenicity of 
the strains. Reporting full antimicrobial resistance pro-
files along with the frequency of resistance to individ-
ual drugs for at-risk population is a change in approch 
to reporting AMR data and a step closer to the new 
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concept of case-based surveillance of AMR. Of par-
ticular concern is the emergence of resistance to Q–D 
that has never been licensed for clinical use in Serbia 
nor has ever been a part of therapeutic protocols in our 
country. The illicit usage of antibiotics in animal farm-
ing could be implicated. MLVA revealed polyclonal 
setting with 25 unique MT profiles that were most 
likely selected through antibiotic pressure. This study 
also contributes to the investigation of VREfm geno-
type distribution in the neighboring countries within 
the Balkan peninsula. Close monitoring of the pattern 
of resistance, implementation of specific guidelines, 
cleaning procedures and antibiotic stewardship policy, 
as well as the introduction of VRE screening among 
at-risk inpatients, as part of active surveillance are 
urgently needed in Serbia.
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